Drug Trial Radar · NCT02753530
Study of Arimoclomol in Inclusion Body Myositis (IBM)
Last checked: Nov 19, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Aug 16, 2017
Primary completion
Jan 11, 2021
Study completion Jan 11, 2021
Sponsor
- Lead sponsor
- ZevraDenmarkIndustry
- Sponsor type
- Industry
- Collaborators
- University of Kansas Medical Center; University College, London
- First posted
- Apr 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Funding Source - FDA Office of Orphan Products Development (OOPD). The purpose of this study is to evaluate the safety and efficacy of the study drug, arimoclomol in IBM patients.
Conditions
- Inclusion Body Myositis
Interventions
ArimoclomolDrug
2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
PlaceboOther
2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total ScoreTime frame: Change from Baseline to Month 20
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Phoenix Neurological Associates
Phoenix, Arizona
University of California, Irvine
Irvine, California
University of Colorado School of Medicine
Aurora, Colorado
University of Kansas Medical Center
Kansas City, Kansas
Johns Hopkins University
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
University of Rochester
Rochester, New York
The Ohio State University
Columbus, Ohio
Nerve and Muscle Center of Texas
Houston, Texas
University of Utah
Salt Lake City, Utah
University of Virginia
Charlottesville, Virginia
University College of London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.